# Improving Immunosuppressive Treatment for Patients With Severe Aplastic Anemia

> **NCT00061360** · PHASE2 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 77 (actual)

## Conditions studied

- Severe Aplastic Anemia

## Interventions

- **DRUG:** ATG+Rapamune+cyclosporine
- **DRUG:** ATG+cyclosporine

## Key facts

- **NCT ID:** NCT00061360
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06-26
- **Primary completion:** 2006-02-15
- **Final completion:** 2015-09-08
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2021-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00061360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00061360, "Improving Immunosuppressive Treatment for Patients With Severe Aplastic Anemia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00061360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*